Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker BOLT
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Renaissance Technologies Holdings Corporation | 92,925 | 4.8% | SCHEDULE 13G/A ↗ |
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Renaissance Technologies LLC | 92,925 | 4.8% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G | BOLT Bolt Biotherapeutics, Inc. | Matthew D. Perry | 412,416 | 17.5% | SCHEDULE 13G ↗ |
| Nov 6, 2026 | SCHEDULE 13G | BOLT Bolt Biotherapeutics, Inc. | Coastlands Capital LLC | 412,416 | 17.5% | SCHEDULE 13G ↗ |
| Nov 6, 2026 | SCHEDULE 13G | BOLT Bolt Biotherapeutics, Inc. | Coastlands Capital GP LLC | 412,416 | 17.5% | SCHEDULE 13G ↗ |
| Nov 6, 2026 | SCHEDULE 13G | BOLT Bolt Biotherapeutics, Inc. | Coastlands Capital Partners LP | 412,416 | 17.5% | SCHEDULE 13G ↗ |
| Nov 6, 2026 | SCHEDULE 13G | BOLT Bolt Biotherapeutics, Inc. | Coastlands Capital LP | 412,416 | 17.5% | SCHEDULE 13G ↗ |
| Aug 13, 2026 | SCHEDULE 13G | BOLT Bolt Biotherapeutics, Inc. | Renaissance Technologies Holdings Corporation | 98,625 | 5.1% | SCHEDULE 13G ↗ |
| Aug 13, 2026 | SCHEDULE 13G | BOLT Bolt Biotherapeutics, Inc. | Renaissance Technologies LLC | 98,625 | 5.1% | SCHEDULE 13G ↗ |
| Feb 26, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | NFLS Platform Holdings Limited | 29,930 | 1.6% | SCHEDULE 13D/A ↗ |
| Feb 26, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | NFLS Beta Limited | 29,930 | 1.6% | SCHEDULE 13D/A ↗ |
| Feb 26, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Permwell Management Limited | 5,000 | 0.3% | SCHEDULE 13D/A ↗ |
| Feb 26, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Nan Fung Life Sciences Holdings Limited | 82,486 | 4.3% | SCHEDULE 13D/A ↗ |
| Feb 26, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Pivotal Life Sciences Holdings Limited | 52,556 | 2.7% | SCHEDULE 13D/A ↗ |
| Feb 26, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Pivotal Partners Ltd | 52,556 | 2.7% | SCHEDULE 13D/A ↗ |
| Feb 26, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Pivotal bioVenture Partners Fund I U.G.P. Ltd. | 52,556 | 2.7% | SCHEDULE 13D/A ↗ |
| Feb 26, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Pivotal bioVenture Partners Fund I G.P., L.P. | 52,556 | 2.7% | SCHEDULE 13D/A ↗ |
| Feb 26, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Pivotal bioVenture Partners Fund I, L.P. | 52,556 | 2.7% | SCHEDULE 13D/A ↗ |
| Feb 26, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | NF Investment Holdings Limited | 87,486 | 4.6% | SCHEDULE 13D/A ↗ |
| Feb 26, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Nan Fung Group Holdings Limited | 87,486 | 4.6% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | NFLS Platform Holdings Limited | 44,674 | 2.3% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | NFLS Beta Limited | 44,674 | 2.3% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Permwell Management Limited | 5,000 | 0.3% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Nan Fung Life Sciences Holdings Limited | 123,119 | 6.4% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Pivotal Life Sciences Holdings Limited | 78,445 | 4.1% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Pivotal Partners Ltd | 78,445 | 4.1% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Pivotal bioVenture Partners Fund I U.G.P. Ltd. | 78,445 | 4.1% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Pivotal bioVenture Partners Fund I G.P., L.P. | 78,445 | 4.1% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Pivotal bioVenture Partners Fund I, L.P. | 78,445 | 4.1% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | NF Investment Holdings Limited | 128,119 | 6.7% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13D/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Nan Fung Group Holdings Limited | 128,119 | 6.7% | SCHEDULE 13D/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Vivo Panda, LLC | 72,414 | 3.8% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Vivo Panda Fund, L.P. | 72,414 | 3.8% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Vivo Capital VIII, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Vivo Capital Surplus Fund VIII, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Vivo Capital Fund VIII, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Tang Capital Partners IV, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Tang Capital Partners III, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Tang Capital Partners International, LP | 29,204 | 1.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Tang Capital Partners, LP | 37,675 | 2.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Kevin Tang | 66,879 | 3.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Tang Capital Management, LLC | 66,879 | 3.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Tang Capital Partners IV, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Tang Capital Partners III, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Tang Capital Partners International, LP | 29,204 | 1.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Tang Capital Partners, LP | 37,675 | 2.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Kevin Tang | 66,879 | 3.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Tang Capital Management, LLC | 66,879 | 3.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Tang Capital Partners IV, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | BOLT Bolt Biotherapeutics, Inc. | Tang Capital Partners III, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:38 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances